Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

NCT05266404 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Interventions

DRUG: Dapagliflozin/sitagliptin FDC
DRUG: Sitagliptin
DRUG: Dapagliflozin

Sponsor

AstraZeneca

Collaborators

[object Object]